PEGASYS 180

Indications

• Chronic Hepatitis B
• Chronic Hepatitis C
• Certain types of cancer, such as melanoma and hairy cell leukemia

Dosage

Children: Refer to the BNF for Children for appropriate dosing information.

Adults: Refer to the specific product's prescribing information for dosing; typically, dosing is determined based on the condition being treated and the patient's weight.

Mechanism of action

Peginterferon exerts its effects by binding to specific receptors on the surface of cells, activating the JAK-STAT signaling pathway. This leads to the transcription of interferon-stimulated genes that mediate antiviral, antiproliferative, and immunomodulatory effects. The drug enhances both the innate and adaptive immune responses, promoting the activity of natural killer cells and cytotoxic T lymphocytes.

Pharmacodynamics

Peginterferon has a long half-life due to its pegylation, which prevents rapid degradation and renal clearance. This results in sustained levels of the drug in circulation, allowing for once-weekly dosing in many cases. The pharmacodynamic effects include increased antiviral activity, modulation of immune response, and potential antiproliferative effects in neoplastic conditions. The drug's efficacy is enhanced by its ability to induce a sustained virological response in chronic viral infections.

Pharmacokinetics

Peginterferon demonstrates linear pharmacokinetics with a prolonged elimination half-life due to its pegylation. Peak plasma concentrations are reached approximately 24 to 48 hours post-injection. The drug is primarily eliminated via hepatic metabolism and renal excretion of metabolites. Its pharmacokinetic profile allows for less frequent dosing compared to unmodified interferons, improving patient adherence.

Contra-indications

• Hypersensitivity to peginterferon or any of its components
• Severe liver disease
• Autoimmune disorders
• History of severe psychiatric disorders

Adverse effects

• Flu-like symptoms (fever, chills, fatigue)
• Headache
• Nausea
• Vomiting
• Diarrhea
• Depression
• Anxiety
• Myalgia
• Injection site reactions
• Hematological abnormalities (e.g., leukopenia, thrombocytopenia)

Interactions

• Caution with other drugs that may cause bone marrow suppression
• May enhance the effects of other medications with similar adverse effect profiles

Precautions

• Monitor for signs of depression and suicidal ideation
• Regular blood counts are recommended during treatment
• Consider dose adjustment in patients with renal impairment

Pregnancy

Peginterferon is classified as category C. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether peginterferon is excreted in human milk. Caution should be exercised when administering to breastfeeding women.

Storage

Store in a refrigerator (2-8 degrees Celsius). Do not freeze. Protect from light.

Formulations

• Peginterferon alfa-2a (subcutaneous injection)
• Peginterferon alfa-2b (subcutaneous injection)